IP Library Granted Patent US 9,284,526
Granted Patent B2
US 9,284,526 · App. 10/979,758 · Granted Mar 15, 2016

Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin

Inventors: Roberto Olivieri (Siena, IT); Fabio Sabbatini (Monteroni d'Arbia, IT); Maria Kontakou (Caserta, IT); Lucia Tagliaferri (Siena, IT); Antonella Giglioli (Siena, IT); Rino Rappuoli (Monteriggioni, IT)
Assignee: GSK Vaccines S.R.L.
C12N1/20C12R1/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,284,526
App. No.
10/979,758
Granted
Mar 15, 2016
Kind
B2
Abstract

The present invention relates to a medium containing non-animal derived proteinaceous material for cultivating patheogenic bacteria to produce an immunogenic factor and processes employing such medium.

Claims (4)

1. A medium for cultivating Haemophilus influenzae to produce an immunogenic factor wherein the medium comprises a Haemophilus influenzae bacteria and at least about 50% by dry weight of a non-animal derived proteinaceous material, and which does not comprise animal derived proteinaceous material, wherein the non-animal derived proteinaceous material is a soybean derived protein composition.

2. A process for preparing an immunogenic factor of the Haemophilus influenzae bacteria comprising the steps of cultivating the Haemophilus influenzae bacteria in a medium comprising at least about 50% by dry weight of a non-animal derived proteinaceous material, wherein the medium does not comprise animal derived proteinaceous material and the non-animal derived proteinaceous material is a soybean derived protein composition.

3. The method of claim 2 , further comprising purifying the immunogenic factor from the medium.

4. A process for the production of a vaccine comprising preparing an immunogenic factor of Haemophilus influenzae by the process of claim 3 , and bringing said factor, optionally toxoided, into association with a pharmaceutically acceptable carrier.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2016
From: OLIVIERI, ROBERTO; SABBATINI, FABIO; KONTAKOU, MARIA; TAGLIAFERRI, LUCIA; GIGLIOLI, ANTONELLA; RAPPUOLI, RINO
To: CHIRON S.P.A.
Reel/Frame 037632/0624 →
CHANGE OF NAME Recorded Feb 1, 2016
From: CHIRON S.P.A.
To: CHIRON S.R.L.
Reel/Frame 037672/0411 →
CHANGE OF NAME Recorded Feb 1, 2016
From: CHIRON S.R.L.
To: NOVARTIS VACCINE AND DIAGNOSTICS SRL.
Reel/Frame 037673/0522 →
CHANGE OF NAME Recorded Feb 1, 2016
From: NOVARTIS VACCINE AND DIAGNOSTICS SRL.
To: GSK VACCINES S.R.L.
Reel/Frame 037683/0471 →
Priority Claims (2)
GB 9710981.3 · May 28, 1997 · national
GB 9806802.6 · Mar 30, 1998 · national
Continuity (4)
Continuation 10383001 · Mar 7, 2003
Continuation 09424800 · Feb 24, 2000
Continuation PCTIB9800938 · May 28, 1998
Related Publication 20050089968A1 · Apr 28, 2005